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cardiomyopathies. LVNC has been reported in up to 40% of the general population, raising questions about whether it is
a distinct pathological entity, a remodeling epiphenomenon, or merely an anatomical phenotype.
OBJECTIVES The authors determined the prevalence and predictors of LVNC in a healthy population using 4 cardiac
magnetic resonance imaging diagnostic criteria.
METHODS Volunteers >40 years of age (N ¼ 1,651) with no history of cardiovascular disease (CVD), a 10-year risk of
CVD < 20%, and a B-type natriuretic peptide level greater than their gender-speciﬁc median underwent magnetic
resonance imaging scan as part of the TASCFORCE (Tayside Screening for Cardiac Events) study. LVNC ratios were
measured on the horizontal and vertical long axis cine sequences. All individuals with a noncompaction ratio of $2
underwent short axis systolic and diastolic LVNC ratio measurements, and quantiﬁcation of noncompacted and com-
pacted myocardial mass ratios. Those who met all 4 criteria were considered to have LVNC.
RESULTS Of 1,480 participants analyzed, 219 (14.8%) met $1 diagnostic criterion for LVNC, 117 (7.9%) met 2 criteria,
63 (4.3%) met 3 criteria, and 19 (1.3%) met all 4 diagnostic criteria. There was no difference in demographic or allometric
measures between those with and without LVNC. Long axis noncompaction ratios were the least speciﬁc, with
current diagnostic criteria positive in 219 (14.8%), whereas the noncompacted to compacted myocardial mass ratio was
the most speciﬁc, only being met in 61 (4.4%).
CONCLUSIONS A signiﬁcant proportion of an asymptomatic population free from CVD satisfy all currently used
cardiac magnetic resonance imaging diagnostic criteria for LVNC, suggesting that those criteria have poor speciﬁcity
for LVNC, or that LVNC is an anatomical phenotype rather than a distinct cardiomyopathy. (J Am Coll Cardiol
2016;68:2157–65) © 2016 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
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ABBR EV I A T I ON S
AND ACRONYMS
BNP = B-type natriuretic
peptide
CMR = cardiac magnetic
resonance imaging
CVD = cardiovascular disease
LVEDV = left ventricular
end-diastolic volume
LVEF = left ventricular ejection
fraction
LVESV = left ventricular
end-systolic volume
LVGFI = left ventricular global
function index
LVMVR = left ventricular mass
volume ratio
LVNC = left ventricular
noncompaction
LVSV = left ventricular stroke
volume
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2158proliferation in publications regarding this
entity, raising the question of whether this is
a result of better identiﬁcation of those with
the disease or whether it is being over-
diagnosed due to the rapid expansion in the
utilization of cardiac imaging and the ever-
improving visualization of cardiac structures
(4,5). More than 8% of athletes meet 1 of the
3 current echocardiographic criteria for
LVNC, whereas 43% of a healthy population
cohort meet the most commonly used cardiac
magnetic resonance imaging (CMR) threshold
for diagnosis measured on long axis cine se-
quences as proposed by Peterson et al. (6–8).
In addition, a high prevalence of LVNC has
been observed in both dilated and hypertro-
phic cardiomyopathies (9,10).SEE PAGE 2182Since the original CMR criteria was proposed
by Petersen et al. (7), several other groups have
developed alternate diagnostic criteria with improved
sensitivity and speciﬁcity, utilizing measurements on
both short axis systolic and diastolic views of the left
ventricle as well as quantifying the compacted-to-
noncompacted myocardial mass ratio (11–13). How-
ever, given the earlier ﬁndings from multiple studies
utilizing multiple imaging modalities of signiﬁcant
noncompaction in asymptomatic cohorts free from
known cardiovascular disease (CVD), it is not clear
whether these new criteria help identify those with
genuine disease, or whether, when applied to the
general population, they will serve to further
strengthen the notion of LVNC as an anatomical
phenotype rather than a pathological entity. This is of
signiﬁcant clinical importance due to the long-term
implications that currently receiving a diagnosis of
LVNC entails—impacting insurance costs and neces-
sitating long-term monitoring and follow-up. The aim
of this study was to determine the prevalence of the
population exhibiting LVNC, the predictors for the
presence LVNC, and the physiological implications of
noncompaction on cardiac function.
METHODS
STUDY POPULATION. Following local ethical com-
mittee approval, a cohort of 2,047 volunteers was
invited to the imaging arm of the TASCFORCE (Tay-
side Screening for Cardiovascular Events) study. Vol-
unteers were enrolled into the study if they: 1) were
more than 40 years of age; 2) were free from CVD or
other indication for statin therapy as recommended bythe Scottish Intercollegiate Guidelines Network (SIGN)
report 97 for “Risk Estimation and the Prevention of
Cardiovascular Disease” published in February 2007;
3) had a serum B-type natriuretic peptide (BNP) level
greater than their gender speciﬁc median; and 4) had a
10-year risk of coronary heart disease <20% as pre-
dicted by the Adult Treatment Panel III algorithm (14).
Exclusion criteria included the following: 1) preg-
nancy; 2) known primary muscle disease; 3) known
atherosclerotic disease—including angina, previous
myocardial infarction, peripheral arterial disease,
amputation, previous revascularization surgery, hy-
pertension, heart failure, or cerebrovascular event; 4)
known diabetes; 5) active liver disease; 6) other
known illness or contraindication to magnetic reso-
nance imaging (MRI); 7) participation in another clin-
ical trial; 8) inability to give informed consent; 9)
known alcohol abuse; and 10) a blood pressure >145/
95 mm Hg. Details of the TASCFORCE study arms and
design are encapsulated within Figure 1.
IMAGE ACQUISITION. The MRI protocol has been
described in detail elsewhere (15). In brief, imaging
was performed using a 3-T Magnetom Trio Scanner
(Siemens, Erlangen, Germany). Whole-body magnetic
resonance angiography was performed using a dual-
bolus injection technique with the CMR cines per-
formed before the ﬁrst contrast injection, and the late
gadolinium enhancement sequences performed be-
tween the ﬁrst and second contrast bolus injections.
For CMR, a body matrix radiofrequency coil (6 ele-
ments) was used in combination with a spine array
(up to 24 elements).
Electrocardiograph (EKG)–gated segmented breath-
hold cinematic (CINE) TrueFISP (Siemens, Erlangen,
Germany) images were acquired in the horizontal
and vertical long axes, and in the short axis from
the atrioventricular ring to the left ventricular (LV)
apex using a 2-dimensional ECG-gated breath-hold
segmented (CINE) TrueFISP sequence. Retrospective
ECG gating was used, with 25 cardiac phases recon-
structed (25 lines per segment) and 2 image slices ac-
quired per breath-hold. Parallel imaging was also
implemented (integrated parallel acquisition tech-
nique [iPAT x2]).
IMAGE ANALYSIS. LV mass and volume quantiﬁca-
tion was performed as previously described (15).
Values were normalized to height1.7. For non-
compaction assessment, each of the 4 diagnostic
criteria was measured as follows (Central Illustration):
1. Long axis noncompaction (LAX) was measured
on the horizontal and vertical LAX cine sequences,
which were analyzed at end-diastole. The thick-
ness of the compacted and noncompacted
FIGURE 1 Consolidated Standards of Reporting Trials Flow Diagram of the Tayside Screening for Cardiac Events Study
Assessed for eligibility (n= 5015)
Did not meet inclusion/exclusion criteria (n=64)
Serious illness (n=16)
Medication (n=20)
Age<40 (n=3)
Pregnant (n=1)
Other (n=24)
Excluded for other reason (n=90)
Lives out of area (n=4)
Unable to obtain blood/refused (n=52)
Unable to calculate risk score (n=30)
Other (n=4)
Cardiovascular risk screen fail (n=438)
Hypertension (n=291)
High cardiovascular risk score (n=146)
Other (n=1)
Allocated to MRI/BNP or BNP groups (n=4423)
BNP group (n=2376) MRI/BNP group (n=2047)
Change to eligibility on
recall (n= 17)
South Asian substudy
patients invited for
scan (n= 20)
Scans not performed (n= 522)
Claustrophobia (n= 83)
Problems with venous access/
technical problems (n=15)
Body habitus (n=3)
Unsafe to scan (n=34)
No consent for scan (n=373)
Did not attend/other (n=14)
Completed scans (n= 1528)
Images suitable for LVNC analysis (n= 1480)
Follow up for CV endpoints by record linkage
Diagram describes the recruitment, exclusions, ﬁnal study numbers, and planned follow-up. BNP ¼ B-type natriuretic peptide;
CV ¼ cardiovascular; LVNC ¼ left ventricular noncompaction; MRI ¼ magnetic resonance imaging.
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2159myocardium was measured at the location of
maximum noncompaction as described by
Petersen et al. (7). Where uncertainty existed,
multiple sites were measured and the maximum
noncompaction ratio recorded. An LAX non-
compacted: compacted myocardial ratio $2.3 was
considered to meet the LAX diagnosis of LVNC (7).
The location of maximum noncompaction was
recorded using the American Heart Association
(AHA) 17-segment model of the left ventricle.2. Short axis noncompaction (SAX) was performed
using the short axis cine images, with the region
of highest noncompacted myocardium to com-
pacted myocardium ratio measured both in dias-
tole and systole, as described by Stacey et al. (12)
and Grothoff et al. (13). The apical LV (segment
17) was excluded from analysis. A diastolic SAX
(SAXDIAS) noncompacted: compacted myocardial
ratio $3 was considered to meet the SAXDIAS diag-
nosis of LVNC, whereas a systolic SAX (SAXSYST)
CENTRAL ILLUSTRATION Measurement of Myocardial Noncompaction Using Each of the 4 Techniques
Weir-McCall, J.R. et al. J Am Coll Cardiol. 2016;68(20):2157–65.
(A, B) Images demonstrate long axis noncompaction ratio measurement (orange line ¼ compacted myocardium, blue line ¼ noncompacted myocardium)
with a maximum long axis noncompaction ratio of 3.4 obtained in the anterior apical wall. (C, D) Images show short axis noncompaction measurements are
demonstrated at diastole (C) where the maximum noncompaction ratio ¼ 3.6 and systole (D) where the maximum noncompaction ratio ¼ 2.2. (E, F) Images
delineate compacted and total myocardial mass contours giving a noncompacted mass of 24% of the total mass.
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TABLE 1 Breakdown of the Currently Used Cardiac Magnetic Resonance
Imaging Diagnostic Criteria for Left Ventricular Noncompaction in the
Whole Population and by Sex
Long-Axis
Short-Axis
Diastole
Short-Axis
Systole
Noncompacted
Mass
All 4
Criteria
Total
(n ¼ 1,480)
186 (12.6) 106 (7.2) 65 (4.4) 61 (4.1) 19 (1.3)
Male
(n ¼ 565)
71 (12.6) 42 (7.4) 20 (3.5) 23 (4.1) 6 (1.1)
Female
(n ¼ 915)
115 (12.6) 64 (7.0) 45 (4.9) 38 (4.2) 13 (1.4)
Values are n (%).
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2161noncompacted:compacted myocardial ratio $2 was
considered to meet the SAXSYST diagnosis of LVNC.
The location of maximum noncompaction in both
systole and diastole was recorded using the AHA
17-segment model of the left ventricle.
3. Noncompacted myocardial mass (NCMASS) was
measured as described by Jacquier et al. (11).
Endocardial and epicardial contours were deﬁned
on the SAX stack at end-diastole with the papillary
muscles included in the compacted mass. A new
endocardial contour was then deﬁned to incorpo-
rate the noncompacted trabeculae to calculate the
global LV mass. The NCMASS was calculated as the
difference between the global LV mass and the
compacted LV mass. A noncompacted mass >20%
of the global LV mass was considered to meet the
NCMASS diagnosis of LVNC.
All individuals had the LAX noncompacted: com-
pacted myocardial ratio measured, however only
those with a maximum LAX noncompacted: com-
pacted myocardial ratio $2 underwent SAXSYST,
SAXDIAST and NCMASS measurements. A lower ratio
threshold of $2 was chosen to widen the population
sampled to ensure adequate capture of all individuals
likely to meet any of the diagnostic criteria.
Those who met all 4 diagnostic criteria for LVNC
were taken as demonstrating the LVNC phenotype.
The Central Illustration demonstrates the measure-
ments performed using the 4 techniques. All analysis
was performed using commercial software (Argus,
Siemens Multi-Modality Work Platform, version VB
15, Seimens) by 1 of 2 observers. Fifteen study data-
sets were read by both observers, with 1 observer
reading them twice to calculate intraobserver and
interobserver variability for each of the 4 measures.
STATISTICAL ANALYSIS. Data are expressed as
mean  SD for continuous variables, median (range)
for ordinal variables and number of patients (%) for
nominal variables. Normality tests were performed;
if the test failed, where possible standard trans-
formations such as square root, reciprocal, or loga-
rithmic transforms were used to generate a Gaussian
distribution. An independent sample Student t test
was used to test the null hypothesis that samples
originate from the same source. Chi-square or
Fisher’s exact tests were used as appropriate to
compare nominal data. Two-way mixed, absolute
agreement, average measure intraclass correlation
coefﬁcients (ICC) for each of the 4 measures of non-
compaction were determined with ICC >0.75 ¼
excellent, 0.4 to 0.75 ¼ good, <0.40 ¼ poor,
and <0.20 ¼ slight. All data were analyzed using SPSS
statistical package (version 21.0, IBM SPSS, Chicago,Illinois). Signiﬁcance was adjusted for multiple com-
parisons using a Bonferroni correction.
RESULTS
Of the 1,528 volunteers who completed the imaging
protocol, 48 were excluded due to inadequate image
quality. This resulted in 1,480 (age 54.1  8.3 years,
38% male) undergoing complete imaging with diag-
nostic quality images allowing measurement of all 4
measures of noncompaction.
The average maximum LAX noncompacted ratio
within the entire cohort was 1.78  0.63. A total of 296
(20.0%) of 1,482 analyzed datasets demonstrated an
LAX ratio of $2 and were therefore included in sub-
sequent analysis. Of the 296 who underwent all
4 diagnostic tests for LVNC, 219 (74%) met at least 1
diagnostic criterion for LVNC, 117 (39.5%) met 2
criteria, 63 (21.3%) met 3 criteria, and 19 (6.4%) met all
4 diagnostic criteria (Table 1). A total of 186 (62.8%)
met the LAX criteria with the most common location
for the maximum LAX noncompaction ratio found in
the apical lateral wall. A total of 106 met the SAXDIAST
(35.8%) criterion, with the most common site of
maximum noncompaction found in the apical lateral
wall (segment 16). A total of 65 (22%) met the SAXSYST
criterion, with the most common site of maximum
noncompaction found in the apical lateral wall
(segment 16). A total of 61 (20.6%) met the NCMASS
criteria. Thus, 14.8% of the normal population met at
least 1 of the current CMR criteria for LVNC, whereas
1.3% met all 4 of the proposed diagnostic criteria for
LVNC.
Those who met all 4 of the diagnostic criteria (and
were therefore considered in our study to exhibit the
LVNC phenotype) demonstrated no signiﬁcant dif-
ferences in demographics, allometric measures, or
cardiovascular risk factors (Table 2). They did however
show signiﬁcantly lower LV mass index (LVMI) (36.1 
9.2 g/m1.7 vs. 42.5  9.5 g/m1.7, p ¼ 0.004), higher LV
end systolic volumes (LVESV) (20.6  6.1 g/m1.7 vs.
TABLE 2 Comparison of Cohort Characteristics Between Those Meeting 1, 2, 3, or 4 Left Ventricular Noncompaction Criteria
Criteria Met 0 1 2 3 4 p Value*
N 1,262 102 54 44 19
Male 480 (38) 47 (46) 19 (35) 16 (36) 6 (32) 0.64
Age, yrs 54.2  8.2 53.9  7.9 53.4  9.0 53.5  9.7 54.1  8.6 0.97
Pulse, beats/min 63.4  9.3 64.3  16.1 62.3  7.9 63.4  10.7 60.3  6.0 0.038
Systolic BP, mm Hg 123  12 123  12 120  11 121  11 118  13 0.10
Diastolic BP, mm Hg 73  9 73  9 71  9 70  8 71  9 0.44
ASSIGN 10-yr risk score 9.4  6.7 8.9  5.6 8.1  5.5 9.4  7.9 8.1  5.2 0.42
Height, m 1.68  0.09 1.68  0.09 1.68  0.08 1.70  0.10 1.67  0.09 0.69
Weight, kg 75.5  14.5 76.1  13.4 75.1  14.1 75.3  13.1 69.9  12.1 0.09
BMI, kg/m2 26.8  4.3 26.9  3.5 26.7  4.6 26.1  3.7 25.0  3.0 0.019
Current smoker 152 (12) 9 (9) 5 (9) 3 (7) 0 (0) 0.15
Ex smoker 328 (26) 30 (29) 15 (28) 18 (39) 5 (26) 1.00
Nonsmoker 482 (62) 61 (61) 34 (63) 23 (52) 14 (68) 0.64
Smoking pack-yrs 6.0  11.7 8.2  16.5 4.7  9.1 4.6  8.2 6.3  12.9 0.90
FH of CVD 328 (26) 26 (25) 13 (24) 12 (27) 6 (32) 0.60
Total cholesterol, mmol/l 5.49  0.98 5.28  0.78 5.38  0.85 5.60  1.21 5.33  0.96 0.48
LDL cholesterol, mmol/l 3.40  0.88 3.27  0.76 3.27  0.72 3.51  1.11 3.43  0.81 0.88
HDL cholesterol, mmol/l 1.44  0.43 1.39  0.42 1.46  0.38 1.43  0.42 1.44  0.37 0.95
Triglycerides, mmol/l 1.48  0.86 1.39  0.79 1.51  1.01 1.51  0.91 1.19  0.59 0.15
Random glucose, mmol/l 5.18  0.92 5.18  0.69 4.99  0.81 5.25  0.97 5.38  0.42 0.56
BNP, pg/ml 27.5  15.6 24.1  13.8 29.4  20.5 32.8  27.3 31.0  23.4 0.39
Values are N, n (%) or mean  SD. N for diagnostic criteria met is mutually exclusive, and based on the maximum number of criteria met by each study participant. *p values are
derived from comparing those meeting 0 criteria and those meeting all 4 criteria, with binary outcome variables compared using the Fisher exact test. Signiﬁcance level set at
p ¼ 0.0025 after Bonferroni correction for multiple comparisons.
ASSIGN ¼ assessing cardiovascular risk using Scottish Intercollegiate Guidelines Network; BMI ¼ body mass index; BP ¼ blood pressure; BNP ¼ B-type natriuretic peptide;
CVD ¼ cardiovascular disease; FH ¼ family history; HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein.
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216217.1  5.5 ml/m1.7; p ¼ 0.006), lower ejection fraction
(EF) (64.7 9.2% vs. 69.0 6.5%; p¼0.005), and lower
LV mass volume ratio (LVMVR) (0.62  0.10 g/ml
vs. 0.79  0.15 g/ml; p < 0.001) (Table 3). A signiﬁcant
but weak inverse correlation was seen between sys-
tolic blood pressure and the LAX noncompaction ratio
(B ¼ 0.004; p ¼ 0.001) with an inverse correlation
observed between the degree of myocardial non-
compaction and LV mass (B ¼ 0.006; p < 0.001)
(Table 4).
Repeatability for the LAX measures was good for
intraobserver repeated measures (ICC: 0.59; 95%
conﬁdence interval [CI]: -0.28 to 0.87), and poor forTABLE 3 Comparison of Left Ventricular Measures Between Those M
Criteria Met 0 1
LVM, g/m1.7 42.5  9.5 42.9  10.2 39.8
LVEDV, ml/m1.7 54.5  9.7 55.8  9.2 56.0
LVESV, ml/m1.7 17.1  5.5 17.7  5.3 18.
LVSV, ml/m1.7 37.4  6.5 38.1  6.0 37.9
LVEF, % 69.0  6.5 68.7  6.1 67.8
LVMVR, g/ml 0.79  0.15 0.77  0.14 0.72
Values are mean  SD.
LVEDV¼ left ventricular end-diastolic volume; LVEF ¼ left ventricular ejection fraction
left ventricular mass volume ratio; LVSV ¼ left ventricular stroke volume.interobserver measures (ICC: 0.28; 95% CI: 1.3 to
0.76). Repeatability for the SAXDIAS measures was
good for intraobserver repeated measures (ICC: 0.65;
95% CI: 7.42 to 0.57), and good for interobserver
measures (ICC: 0.73; 95% CI: -0.18 to 0.93). Repeat-
ability for the SAXSYST measures was only slight for
intraobserver repeated measures (ICC: 0.19; 95%
CI: 1.92 to 0.77), and good for interobserver mea-
sures (ICC: 0.50; 95% CI: 0.49 to 0.87). Repeatability
for the NCMASS measures was good for intraobserver
repeated measures (ICC: 0.70; 95% CI: 0.08 to 0.92),
and excellent for interobserver measures (ICC: 0.88;
95% CI: 0.51 to 0.97).eeting 1, 2, 3, or 4 Left Ventricular Noncompaction Criteria
2 3 4 p Value
 10.2 39.9  8.3 36.1  9.2 0.004
 12.2 57.5  10.5 58.7  2.7 0.069
1  5.4 18.6  5.7 20.6  6.1 0.006
 8.4 38.9  6.4 38.0  9.7 0.78
 5.5 68.1  5.9 64.7  9.2 0.005
 0.11 0.70  0.13 0.62  0.10 <0.001
; LVESV ¼ left ventricular end-systolic volume; LVM ¼ left ventricular mass; LVMVR¼
TABLE 4 Linear Regression Coefﬁcients Change in the
“Maximum Long Axis Noncompaction Ratio” Per Unit Increase in
Demographic, Biochemical, and Cardiac Magnetic Resonance
Imaging Measures
B SE Intercept p Value
N 1,480
Sex 0.011 0.034 1.75 0.75
Age, yrs 0.001 0.002 1.78 0.79
Pulse, beats/min 0.002 0.002 1.87 0.26
Systolic BP, mm Hg 0.004 0.001 2.29 0.001
Diastolic BP, mm Hg 0.003 0.002 1.99 0.073
ASSIGN risk score, % 0.003 0.003 1.78 0.28
Height, m 0.12 0.18 1.55 0.50
Weight, kg 0.00 0.001 1.76 0.91
BMI, kg/m2 0.002 0.004 1.81 0.60
Smoking pack-yrs 0.00 0.001 1.76 0.93
Total cholesterol, mmol/l 0.02 0.017 1.89 0.16
LDL-cholesterol, mmol/l 0.006 0.039 1.85 0.75
HDL-cholesterol, mmol/l 0.06 0.02 1.78 0.11
Triglycerides, mmol/l 0.02 0.019 1.78 0.36
Random glucose, mmol/l 0.008 0.027 1.72 0.77
BNP, pg/ml 0.000 0.001 1.75 0.95
LVM, g/m2 0.006 0.002 2.02 <0.001
LVEDV, ml/m2 0.005 0.002 1.48 0.003
LVESV, ml/m2 0.008 0.003 1.63 0.012
LVSV, ml/m2 0.006 0.003 1.54 0.02
LVEF, % 0.004 0.003 2.00 0.17
LVMVR, g/ml 0.78 0.11 2.37 <0.001
B ¼ gradient; SE ¼ standard error; other abbreviations as in Tables 2 and 3.
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In our study, almost 15% of the population meet at
least 1 of the current CMR diagnostic criteria for
LVNC, and 1.3% of an asymptomatic population free
from known CVD meet all 4 current CMR criteria. In
addition, we demonstrated that the presence of LVNC
is not associated with demographics, body shape, or
biochemical markers of CVD.
Our ﬁndings are comparable with previous work in
the MESA (Multi Ethnic Study of Atherosclerosis)
population, in which an LAX noncompaction ratio
>2.3 was observed in 43% of 323 participants free
from cardiac disease and hypertension (8). The lower
incidence in our cohort is likely due to 2 factors. The
ﬁrst is the additional use of the LV outﬂow tract LAX
view of the LV in the MESA cohort, thereby
increasing the likelihood of detecting a region of
greater noncompaction using 3 LAX views compared
with 2 views alone. The second is the multiethnic
cohort examined in this previous study, since there
is a greater noncompacted mass in healthy blacks
compared with healthy whites (6,16). We have thusvalidated the previous observations made in the
MESA cohort within a second, much larger popula-
tion study, and further developed and strengthened
the original observations demonstrating that even
when alternate or more stringent combined criteria
are used, a signiﬁcant proportion of the general
population would still be considered to have LVNC. A
signiﬁcant but weak correlation was seen between
systolic blood pressure and LAX noncompaction ra-
tios, consistent with prior observations by others
(17). No correlation was seen between allometric
measures and noncompaction ratios, suggesting that
the presence and thickness of trabeculations are not
determined by body size or composition. In our
study we observed that those with LVNC had a
higher ESV with a lower LV mass (LVM) and EF.
Previous work in the Framingham study has shown
that inclusion of the trabeculae within the myocar-
dial mass contours results in a signiﬁcant increase in
LVM and a decrease in LV volumes consistent with
our observations (18). Thus, these ﬁndings are most
likely due to the technique used for the measure-
ments of mass, volume, and function in the current
study in which trabeculations were included in the
blood pool rather than within the LVM. However,
follow-up of this cohort is required to conﬁrm that
this is the case and that these ﬁndings are not
indicative of early pathological changes. Interest-
ingly, although a difference in LV metrics was
observed between groups when only those meeting
all 4 criteria were looked at, only a very weak cor-
relation was seen between the noncompaction ratio
and LV measures when only the LAX measure was
used. This suggests that LAX noncompaction is not
only the least speciﬁc criterion (resulting in the most
over diagnosis) in our study cohort, but also has
limited implications for LV remodeling.
The observation of high incidence of LVNC in 2
separate population studies indicates 1 of 2 possibil-
ities. One is that the current diagnostic criteria lack
speciﬁcity for the accurate identiﬁcation and diag-
nosis of LVNC, with resultant extensive over diag-
nosis in normal individuals. Indeed, the poor
correlation between the measures, with 15% of the
study cohort meeting at least 1 criterion but <2%
meeting all 4, suggest that the feature they are
measuring is poorly captured by any 1 of the tech-
niques. This is in keeping with previous observations
using echocardiographic diagnostic criteria in which,
in a population with known heart failure and diag-
nosis of LVNC, only 29.8% met all 3 criteria, whereas
36.3% fulﬁlled only 1 criterion (19). In the current
study we have not assessed the use of fractal analysis,
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The
current cardiac MRI criteria for diagnosis of LVNC
lead to over-representation of its frequency in
asymptomatic patients without other manifestations
of heart disease. This suggests that LVNC is an
anatomical phenotype rather than a distinct
cardiomyopathy.
TRANSLATIONAL OUTLOOK: Further studies are
needed to validate more speciﬁc, comprehensive
criteria beyond simple anatomical measures on cardiac
imaging that identify patients with LVNC at risk of
developing adverse clinical events such as arrhythmia,
heart failure, or thromboembolism.
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2164which has been previously described to better
differentiate healthy volunteers from those with
pathological LVNC (20). While this holds some po-
tential, it must be noted that the cohort in whom they
demonstrated a lack of over-diagnosis was free from
hypertension and nonobese. Because both of these
increase trabecular complexity, its ability to differ-
entiate a typical patient presenting with shortness of
breath and both of these comorbidities from true
LVNC remains to be proven. Finally, trabecular
complexity using fractal analysis in both gene-
negative and gene-positive hypertrophic cardiomy-
opathy is both within the same diagnostic range seen
in LVNC. Thus, its speciﬁcity in the diagnosis of LVNC
is questionable (10). One potential solution has been
proposed that moves from a purely imaging-based
diagnosis to a diagnosis that is more holistic and
closer to that of arrhythmogenic right ventricular
cardiomyopathy — requiring, in addition to meeting
imaging criteria either a family member with LVNC, a
regional wall motion abnormality, LVNC-related
complications (arrhythmia, heart failure, or throm-
boembolism), or carrier status of a genetic mutation
known to be associated with LVNC (21).
The second possibility is that noncompaction is an
anatomical phenotype rather than a pathological
cardiomyopathy. At 10-year follow-up of the afore-
mentioned MESA study, those who met the Peterson
et al. (7) criterion for LVNC demonstrated no signiﬁ-
cant difference in LVEF over the follow-up period,
nor any difference in cardiovascular events compared
to those who did not meet the criterion (22). Planned
5- and 10-year follow-up within our TASCFORCE
study group will provide further useful information
on the clinical impact of noncompaction within this
population. It may simply be that those currently
diagnosed with LVNC are those with the anatomical
LVNC phenotype who subsequently develop dilated
or hypertrophic cardiomyopathy. The argument in
favor of this is strengthened by a recent study in
patients with heart failure that demonstrated a lack
of signiﬁcant association between noncompaction
ratios and subsequent major adverse cardiovascular
events (9).
STUDY LIMITATIONS. First, we only conducted a full
analysis of all diagnostic criteria in those with an
LAX ratio of $2, and thus may have underestimated
the total number who may have met 1 or more of the
other 3 diagnostic criteria. However, this is only
likely to further strengthen our observation of
overdiagnosis if more participants without this cri-
terion happened to meet 1 of the other 3 criteria.Second, a selection criterion for recruitment into the
imaging arm of the TASCFORCE study was BNP
above the gender speciﬁc median. Given the known
association between BNP and heart failure, this
could bias the results towards detecting a higher
prevalence of a phenotype that is traditionally
associated with heart failure and a poor clinical
outcome. It could also increase the prevalence of
those with diastolic dysfunction, which may in turn
affect trabeculation quantiﬁcation if there is a sig-
niﬁcant remodeling epiphenomenon component to
these measures. No previous reports have described
an association between these 2, nor is there any
evidence of absence of association. However, of
some reassurance, we did not observe any correla-
tion between BNP and noncompaction ratios, nor
were BNP levels signiﬁcantly higher in those who
met all 4 criteria, suggesting the impact of any po-
tential bias of this is likely to be small.
CONCLUSIONS
A signiﬁcant proportion of an asymptomatic popula-
tion free from CVD satisfy all currently used CMR
diagnostic criteria for LVNC, suggesting that either
these all have poor speciﬁcity for LVNC, or that LVNC
is an anatomical phenotype rather than a distinct
cardiomyopathy.
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